Matthew D. Dallas

Matthew D. Dallas is a declared insider of CoLucid Pharmaceuticals, Inc., with filings sourced from SEC (Form 4). Between 4 March 2016 and 1 March 2017, the trades on record add up to 5 filings.

Sales make up the whole of the open-market record (2 sales, €100k). Other entries cover 1 share grant. In 2017 alone, the filings show no purchases and 1 sale.

The latest filing, published on 1 March 2017, reports a transaction of €119k in CoLucid Pharmaceuticals, Inc. Half of the filings or more reach the SEC (Form 4) feed on the day of the trade. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.